A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

• Status: Recruiting
• Trial end date: 2023-11-01

Summary

This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed patients with multiple myeloma that are not eligible for autologous stem cell transplantation.

• Phase: Phase 2

Details

• Lead Sponsor: Canadian Myeloma Research Group; Myeloma Canada Research Network
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: BB 1101; Bortezomib; Cyclophosphamide; Dexamethasone; Dexamethasone acetate; Pembrolizumab